ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates
MHRA Drug Safety Updates

 

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Drug Safety Update MHRA June-2021-DSU-PDF.pdf

Drug Safety Update MHRA June-2021-DSU-PDF.pdf
Summary: CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases. Atezolizumab (Tecentriq▼) and other immune-stimulatory anticancer drugs: risk of severe cutaneous adverse reactions (SCARs) .COVID-19 vaccines: updates for June 2021
File Size: 226KB
File Type: application/pdf
Created: 17 June 2021
Last Modified: 08 July 2021